BioAge Labs, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kristen Fortney
- Full Time Employees
- 62
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1445A South 50th Street Emeryville CA United States of America 94804
- IPO Date
- Sep 26, 2024
- CIK
- 0001709941
- Website
- bioagelabs.com
- Similar Companies
- Business
- BioAge Labs, Inc. (BIOA) is a clinical-stage biopharmaceutical company that develops therapies targeting the biology of human aging to treat metabolic diseases including obesity, cardiometabolic disorders, and neuroinflammation-driven conditions; its proprietary human-centric discovery platform analyzes multi-omics datasets from longevity cohorts to identify molecular targets and pathways underlying age-related decline. The company's lead product candidate is BGE-102 (azelaprag), an orally available, brain-penetrant NLRP3 inhibitor advancing toward Phase 1 trials in the second half of 2025 for obesity and related indications, complemented by a portfolio of structurally novel APJ receptor agonists such as oral small molecules and long-acting injectables designed to enhance weight loss, preserve muscle, and address insulin resistance in older adults, alongside preclinical programs focused on chronic inflammation and metabolic aging pathways. Founded in 2015 and headquartered in Richmond, California, BioAge operates globally with a focus on North American clinical development and serves pharmaceutical partners and patients with age-associated metabolic conditions. Recent developments include a multi-year research collaboration with Novartis announced in December 2024 to discover targets at the intersection of aging biology and exercise physiology, potentially worth up to $530 million in milestones; a strategic partnership with Lilly ExploR&D in January 2025 for therapeutic antibodies against novel metabolic aging targets; a June 2025 initiative with the HUNT Biobank in Norway to profile over 17,000 samples for drug discovery insights; advancements in its apelin pipeline through antibody partnerships and patent filings for oral APJ agonists; and an initial public offering in September 2024 that bolstered its cash position to fund operations into 2029.
BioAge Labs to Present at Upcoming Investor Conferences
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6% – Should You Sell?
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
BioAge Announces Proposed Public Offering
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk